Our bioinformatic investigation identified UCP2 as a prominent prognostic marker within the UCP family, with high expression associated with unfavorable outcomes in various tumors, response to immunotherapy, and reduced efficacy of radiotherapy in glioma. This evidence concerns the gene UCP2 and central nervous system cancer.